Bayer

Bayer takes control of BlueRock stem cell joint venture

Deal values BlueRock at $1bn. Bayer is buying out private equity partner Versant Ventures and founders in its cell therapy joint venture BlueRock Therapeutics for $240m, three years after setting up ... In addition to the $240m buyout fee, Bayer has also

Transgene slumps as viral cancer therapy fails phase 3 trial

Pexa-Vec (pexastimogene devacirepvec) – one of the new class of oncolytic virus therapies (OVT) – didn’t add to the efficacy of therapy when it was added to treatment with

Bayer bags FDA nod for early prostate cancer drug darolutamide

new competition in the market. Bayer and Orion have US approval for their castration-resistant prostate cancer (CRPC) therapy darolutamide, setting up a market clash with Pfizer/Astellas and Johnson &Johnson. ... Bayer says it has also submitted

Bayer taps Sensyne Health AI and real world data for cardiovascular research

Sensyne a ‘docking station’ for anonymised NHS patient data analysis. Bayer is to work with health tech and AI specialist Sensyne Health to tap into anonymised real world data, in order ... Bayer has two cardiovascular disease candidates in its

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

GW Pharma’s Epidyolex also on the recommended list. Bayer’s Vitrakvi has become the first drug in Europe recommended to treat cancer based on a molecular signature, rather than where

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]